Dandekar Atul sold $210K of MAZE
Dandekar Atul (CSBO) sold 7,500 shares of Maze Therapeutics, Inc. (MAZE) at $28.02 ($0.21M total) on 2026-06-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is a single scheduled open-market transaction by an officer under a 10b5-1 plan; it is more relevant for monitoring insider activity than for forecasting fundamentals.
Market read
This is a routine insider-sale datapoint; it may marginally influence sentiment but lacks new operational or guidance information.
What to watch
Traders may overreact to insider sales; the key is whether there are repeated, non-10b5-1 sales or concurrent operational/regulatory catalysts (not present here).
Background
The article is an SEC Form 4 insider transaction disclosure for Maze Therapeutics, Inc.
Ticker impact
Form 4 shows officer Dandekar Atul sold 7,500 MAZE shares on 2026-06-29 for about $210,150 under a 10b5-1 plan.
Low likelihood of a sustained price move; any impact is likely short-lived unless follow-on filings show unusual activity.
The filing is a disclosed open-market sale by an officer, explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No clear sector read-through; this is company-specific insider transaction disclosure.
None.
None.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish fundamentals.
Key entities
- issuerMaze Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderDandekar Atul
Officer who sold 7,500 shares on 2026-06-29 under a 10b5-1 plan.